Metformin vs. Berberine for Type 2 Diabetes Based on Gene Type
Part of Hormones & metabolism clinical trials.
This trial compares two diabetes medicines, metformin and berberine, in people with newly diagnosed type 2 diabetes. The study looks at how well each medicine works based on a person's specific gene type (TCF7L2). Participants will have their gene tested to see if they carry the TT or CC version of this gene.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 65 years old.
- You have been diagnosed with type 2 diabetes within the last year.
- Your blood sugar test (HbA1c) is between 7.0% and 9.0%.
- You have not used diabetes medicine before, or have used it for 4 weeks or less.
- You are willing to have a genetic test to check your TCF7L2 gene type.
- Your gene test must show either the TT or CC type (not the TC type).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your genes might affect the way your body responds to metformin, a common diabetes medication. It aims to see if a specific genetic variation influences treatment outcomes.
This trial compares two diabetes pills, imeglimin and metformin, to see how they affect energy use in your cells. If you were recently diagnosed with type 2 diabetes and have not taken medication for it, this study might help find the best treatment for you.
This study tests if a berberine-based supplement can help regulate blood sugar and metabolism in people who are overweight and have slightly elevated blood sugar (prediabetes). Participants will take the supplement and maintain their normal lifestyle.
This study tests a new medication called HM15275 to help control blood sugar in people with type 2 diabetes. The trial will check if the medication works well and is safe when added to diet, exercise, or metformin treatment.
This trial compares adding a new pill (cofrogliptin) to increasing your current metformin dose, for people whose blood sugar is still too high despite taking an SGLT2 inhibitor and a low dose of metformin. The goal is to see which option works better and is safer.
This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.
Hear when a new Diabetes Mellitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.